ANO1 amplification and expression may serve as markers for distant metastasis in HNSCC, suggesting CaCC inhibitors as potential therapeutic agents.
May flag high-risk HNSCC for intensified surveillance; leaves open CaCC inhibitor trials in humans.
ANO1 amplification and expression could be markers for distant metastasis in HNSCC. ANO1 overexpression affects cell properties linked to metastasis. Inhibitors of CaCCs could be used to inhibit the tumourigenic properties of ANO1, whereas activators developed to increase CaCC activity could have adverse effects.
No takes yet. Share an insight, caveat, or question.
Ayoub et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: